CSE Talks Ottawa: Six Months After Legalization ... What Now?
Join a panel of experts from Blakes, MNP, and the Canadian Securities Exchange and the cannabis industry for a discussion of the cannabis landscape six months into legalization.
This session will include topics such as upcoming and proposed revised regulations for the edibles industry within this space, trends in the industry in North America as well as the experience of being a publicly listed cannabis company.
CSE-listed issuers operating in the commercial cannabis industry will be on hand to share their perspectives along with legal, accounting and capital markets professionals.
Be sure to RSVP early as space for this event is limited.
For any questions about this event, please contact either Grace Pedota, Listings, Marketing & Events Coordinator at firstname.lastname@example.org or by phone at 416-320-3584 or Scott Pritchard, Senior Advisor, Listings Development - Quebec and Eastern Canada, at email@example.com or by phone at 514-594-6848.
Richard Carleton has been CEO of the Canadian Securities Exchange for seven years. Prior to this appointment, Richard served as Vice-President Corporate Development with responsibility for the CSE’s technology, operations, market data and trading sales teams. Before joining the exchange, Richard worked as a business development consultant in Toronto and New York in the risk management and index product fields after spending twelve years with the Toronto Stock Exchange, serving most recently as a member of the exchange’s senior management team. Active in industry affairs, Richard served two terms as chair of the market data industry’s global trade association in the late 1990's and is a frequent panelist at market structure and trading technology events across North America. Richard also serves as a member of the boards of the Private Capital Markets Association and the Empire Club of Canada.
A member of the Law Society of Upper Canada since 1987, Richard is a graduate of the University of Ottawa (B.A. ’81) and the University of Toronto (LL.B. ’85). He has also completed the executive development programme at the Wharton School, University of Pennsylvania.
CEO & Director, Quadron Cannatech. Co-founder & Executive Director, Cannabis Trade Alliance of Canada
With over 18 years of legal and entrepreneurial experience, Rosy has launched and managed public companies as well as start-ups. She has served as strategic advisor for companies involved in the processing, distribution, and safe use of medical cannabis. Ms. Mondin is the Co-founder & Executive Director at the Cannabis Trade Alliance of Canada and serves as Advisory Board Member for FinCanna Capital Corp and Special Advisor to the Association of Canadian Cannabis Retailers.
In 2014, Rosy founded Soma Labs Scientific which in 2016, amalgamated to form Quadron Cannatech Corporation. In Jan 2017, Quadron listed with the CSE making her the world’s first female CEO of a publicly-traded company within the cannabis industry. In May 2018, Ms. Mondin presented to the Standing Senate Committee and provided valuable insight as to how Health Canada could benefit from implementing new regulations. Most recently, Ms. Mondin won the inaugural ‘Woman in Weed – Trailblazer’ Award at the 2018 Canadian Cannabis Awards and was featured in ‘Women in Weed’ and ‘The Growth Op’ as one of the most influential women in the cannabis space.
As the legal cannabis industry gains traction in Canada, and around the world, Rosy is excited to be on the cusp of this new, fast-growing industry.
Tricia Kuhl's practice focuses on corporate and commercial law, including mergers and acquisitions, commercial transactions, intellectual property, and regulatory matters. She advises clients in a variety of industries, including in the pharmaceutical, technology, fashion and renewable energy sectors in connection with the purchase, sale, licensing, protection, commercialization and transfer of technology, products or other assets. Tricia has advised on numerous share purchase and asset purchase transactions involving private companies, as well as on large public M&A. She has also negotiated a variety of commercial agreements, including shareholder and franchising arrangements and joint ventures. Seconded on three occasions to large pharmaceutical companies in Montréal, Tricia has in-depth experience in the pharmaceutical industry. She has advised companies on advertising, marketing and regulatory compliance issues. She has negotiated clinical trial agreements, intellectual property assignment, transfer, licence and commercialization agreements, and standard operating policies relating to privacy. Tricia has advised clients in the technology sector on complex arrangements relating to all aspects of intellectual property and privacy concerns. She also advises clients in relation to Canada's anti-spam legislation.
55 Colonel By Drive, Ottawa, ON, Canada